Loading organizations...
§ Private Profile · Norwood, MA, USA
Molecular Biometrics is a technology company.
Molecular Biometrics develops accurate, non-invasive diagnostic methodologies leveraging novel metabolomic technologies. The company’s core offering focuses on tools that evaluate normal biologic function, identify markers in disease states, and support drug discovery and development. Their technical approach emphasizes advanced metabolomic profiling to provide insights into biological processes without intrusive procedures.
The company was founded in 2005 by individuals including Hyman Schipper, with James Posillico, PhD, serving as President and CEO, bringing expertise from roles such as Chief Scientific Officer at Cooper Surgical. The foundational insight was to harness the power of metabolomics to create accessible and reliable methods for assessing biological health and disease, moving beyond traditional diagnostic limitations.
Molecular Biometrics aims to serve researchers, diagnostic laboratories, and pharmaceutical companies by providing critical data for understanding disease progression and treatment efficacy. Their long-term vision centers on advancing non-invasive diagnostics, particularly in areas like neurodegenerative conditions, to improve patient care and accelerate therapeutic development through sophisticated biological insights.
Molecular Biometrics has raised $4.0M across 1 funding round.
Molecular Biometrics has raised $4.0M in total across 1 funding round.
Molecular Biometrics has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series B in December 2009.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2009 | $4M Series B | Atlas Venture | Endeavor Venture Funds, Oxford Bioscience Partners, Safeguard Scientifics | Announced |
Molecular Biometrics has raised $4.0M in total across 1 funding round.
Molecular Biometrics's investors include Atlas Venture, Endeavor Venture Funds, Oxford Bioscience Partners, Safeguard Scientifics.
Molecular Biometrics, Inc. is a biotechnology company specializing in metabolomic technologies to develop non-invasive clinical diagnostic tools for personalized medicine, evaluating normal biologic function in health and disease, and supporting drug discovery.[1][2][3][4] Its flagship product, ViaMetrics-E, is a diagnostic assay identifying viable embryos for in vitro fertilization (IVF), addressing reproductive health challenges by improving success rates non-invasively.[1] The company targets fertility clinics, IVF providers, and extends to neurodegenerative diseases (e.g., Parkinson's, Alzheimer's), maternal-fetal medicine, pulmonary conditions, and lactate metabolism, serving healthcare professionals seeking precise, patient-friendly diagnostics.[1][2][4] In 2008, it raised $12-12.5 million in Series B funding to advance R&D and launch ViaMetrics-E in Europe, Japan, and Australia, signaling early growth momentum before apparent dormancy.[1][5]
Founded around 2005, Molecular Biometrics emerged from expertise in metabolomics to pioneer non-invasive tools for reproductive health and beyond, initially headquartered in Chester, NJ, with R&D in New Haven, CT, and Montreal, Quebec, planning a 2009 move to Boston.[1][7] Key early backers included Safeguard Scientifics, which led the 2008 Series B round, drawn to its differentiated tech in molecular diagnostics and strong management trajectory toward global commercialization.[1] Pivotal moments included securing $12-12.5 million to propel ViaMetrics-E from R&D to international launches, marking initial traction in the IVF market amid rising demand for personalized reproductive tools.[1][5] Founders' specifics remain undocumented in available records, but the company's focus crystallized on metabolomics for high-stakes diagnostics like embryo viability.[2][3]
Molecular Biometrics rode the early personalized medicine wave in the late 2000s, leveraging metabolomics—a then-emerging field analyzing small-molecule metabolites—to disrupt invasive diagnostics in reproductive health and neurology.[1][2][4] Timing aligned with surging IVF demand (global market growth) and biotech investor interest in non-invasive tools, amplified by post-genomics shifts toward functional biology readouts.[1][5] Market forces like aging populations boosting neurodegeneration needs and precision repro tech favored its model, influencing the ecosystem by validating metabolomics for embryo selection and paving ways for similar assays in fertility clinics worldwide.[1][3] Though activity appears stalled post-2009 funding (current site pivoted to unrelated gastronomy content), it exemplified early biotech innovation in point-of-care molecular diagnostics.[1][7]
With roots in 2000s biotech funding but no evident activity since, Molecular Biometrics likely faded or pivoted, as its domain now hosts unrelated cooking content, underscoring startup risks in diagnostics.[7] Next steps could involve revival amid modern AI-metabolomics synergies or acquisition by fertility giants like CooperSurgical, fueled by IVF market expansion (projected $30B+ by 2030). Trends like non-invasive repro tech and multi-omics for neurodegeneration will shape any resurgence, potentially amplifying its early influence on personalized health tools—echoing its original promise of accessible, accurate biologic insights.[1][2]